RESUMEN
BACKGROUND: Non-palpable splenomegaly in patients with polycythemia vera (PV) has seldom been addressed. In this retrospective study, we evaluated non-palpable, volumetric splenomegaly defined based on age- and body surface area (BSA)-matched criteria in patients with PV diagnosed according to the 2016 World Health Organization diagnostic criteria. METHODS: Patients with PV who underwent abdominal computed tomography (CT) and who had palpable splenomegaly at diagnosis from January 1991 to December 2020 at Chungnam National University Hospital were enrolled. The spleen volume of each patient was determined by volumetric analysis of abdominal CT and adjusted for the patient's age and BSA. Then the degree of splenomegaly was classified as no splenomegaly, borderline volumetric splenomegaly, overt volumetric splenomegaly, or palpable splenomegaly. RESULTS: Of the 87 PV patients enrolled, 15 (17.2%) had no splenomegaly, whereas 17 (19.5%), 45 (51.7%), and 10 (11.5%) had borderline volumetric, overt volumetric, and palpable splenomegaly, respectively. The degree of splenomegaly did not affect the cumulative incidence of thrombotic vascular events (10-year incidence: 7.7%, 0%, 22.3%, and 50.7%, respectively, P = 0.414). By contrast, splenomegaly tended to adversely affect myelofibrotic transformation (10-year cumulative incidence: 0%, 0%, 7.1%, and 30.3%, respectively, P = 0.062). Moreover, the cumulative incidence of myelofibrotic transformation was significantly higher in patients with overt volumetric or palpable splenomegaly than those with no or borderline volumetric splenomegaly (10-year incidence: 0% vs. 10.3%, respectively; 15-year incidence: 0% vs. 26.3%, respectively, P = 0.020). Overall survival (OS) differed among patients with different degrees of splenomegaly (15-year OS: 100%, 78.6%, 71.7%, and 51.9%, respectively, P = 0.021). CONCLUSION: The degree of splenomegaly, including volumetric splenomegaly, based on age- and BSA-matched reference spleen volumes at diagnosis reflects disease progression in PV patients. Therefore, volumetric splenomegaly should be evaluated at the time of diagnosis and taken into consideration when predicting the prognosis of patients with PV.
Asunto(s)
Policitemia Vera/complicaciones , Valor Predictivo de las Pruebas , Pronóstico , Esplenomegalia/diagnóstico , Esplenomegalia/etiología , Esplenomegalia/fisiopatología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , República de Corea , Estudios Retrospectivos , Adulto JovenRESUMEN
BACKGROUND: The association between COVID-19 infection and the development of autoimmune diseases is currently unknown, but there are already reports presenting induction of different autoantibodies by SARS-CoV-2 infection. Kikuchi-Fuimoto disease (KFD) as a form of histiocytic necrotizing lymphadenitis of unknown origin. OBJECTIVE: Here we present a rare case of KFD with heart involvement after COVID-19 infection. To our best knowledge only a few cases of COVID-19-associated KFD were published so far. Based on presented case, we summarize the clinical course of KFD and its association with autoimmune diseases, as well we discuss the potential causes of perimyocarditis in this case. METHODS: We reviewed the literature regarding cases of "Kikuchi-Fujimoto disease (KFD)" and "COVID-19" and then "KFD" and "heart" or "myocarditis" by searching medical journal databases written in English in PubMed and Google Scholar. RESULTS: Only two cases of KFD after COVID infection have been described so far. CONCLUSION: SARS-CoV-2 infection can also be a new, potential causative agent of developing KFD.
Asunto(s)
COVID-19/fisiopatología , Hepatomegalia/fisiopatología , Linfadenitis Necrotizante Histiocítica/fisiopatología , Miocarditis/fisiopatología , Esplenomegalia/fisiopatología , Disfunción Ventricular Izquierda/fisiopatología , Adulto , COVID-19/complicaciones , Prueba de Ácido Nucleico para COVID-19 , Prueba Serológica para COVID-19 , Ecocardiografía , Hepatomegalia/diagnóstico por imagen , Hepatomegalia/etiología , Linfadenitis Necrotizante Histiocítica/etiología , Linfadenitis Necrotizante Histiocítica/patología , Humanos , Masculino , Miocarditis/diagnóstico por imagen , Miocarditis/etiología , SARS-CoV-2 , Esplenomegalia/diagnóstico por imagen , Esplenomegalia/etiología , Volumen Sistólico , Disfunción Ventricular Izquierda/diagnóstico por imagen , Disfunción Ventricular Izquierda/etiologíaRESUMEN
Splenomegaly can be due to several mechanisms but is almost always a sign of a systemic condition. Patient habits, travel, and medical conditions can increase risk of splenomegaly and suggest etiology. Symptoms can suggest infectious, malignant, hepatic, or hematologic causes. Physical examination will typically reveal splenomegaly, but abdominal ultrasonography is recommended for confirmation. Physical examination should also assess for signs of systemic illness, liver disease, and anemia or other hematologic issues. The most common causes of splenomegaly in the United States are liver disease, malignancy, and infection. Except for apparent causes such as infectious mononucleosis, basic laboratory analysis and ultrasonography are the first-line steps in determining etiology. Malaria and schistosomiasis are common in tropical regions, where as many as 80% of people may have splenomegaly. Management of splenomegaly involves treating the underlying disease process. Splenectomies and spleen reduction therapies are sometimes performed. Any patient with limited splenic function requires increased vaccination and prophylactic antibiotics for procedures involving the respiratory tract. Acute infections, anemia, and splenic rupture are the most common complications of splenomegaly, and people with splenomegaly should refrain from participating in contact sports to decrease risk of rupture.
Asunto(s)
Esplenomegalia/diagnóstico , Esplenomegalia/terapia , Anemia/etiología , Anemia/fisiopatología , Manejo de la Enfermedad , Humanos , Rotura del Bazo/complicaciones , Rotura del Bazo/cirugía , Esplenomegalia/fisiopatología , Ultrasonografía/métodosRESUMEN
BACKGROUND & AIMS: Splenomegaly is usually taken as a consequence of liver cirrhosis. However, as a risk factor for cirrhosis, the impacts of spleen-liver axis on the development of cirrhosis are largely unknown. This study focused on the impacts of splenomegaly on the development of cirrhosis and assessment of the effects of celecoxib, a selective COX-2 inhibitor, on the splenomegaly and cirrhotic liver. MATERIALS AND METHODS: Liver cirrhosis was induced by thioacetamide (TAA). Sixty rats were randomly divided into control, TAA-16w, TAA + celecoxib groups and normal, TAA + sham, TAA + splenectomy groups. Hepatic stellate cells (HSCs) or hepatocytes were co-cultured with splenocytes from those groups. RESULTS: Splenocytes of cirrhotic rats stimulated the HSCs activation and induced hepatocyte apoptosis via enhancing oxidative stress. The hepatic levels of NOX-4 and the in situ O2- were profoundly reduced in TAA + splenectomy group by 50.6% and 18.5% respectively, p < 0.05. Celecoxib significantly decreased the hepatic fibrotic septa induced with TAA by 50.8%, p < 0.05. Splenic lymphoid tissue proliferation and proinflammatory cytokines of the cirrhotic rats were also obviously suppressed by celecoxib, p < 0.05. Compared with the HSC or hepatocyte cell line co-cultured with the cirrhotic splenocytes, the expression of alpha-SMA, NOX-4, in situ O2- or the levels of cleaved caspase3 and NOX-4 were significantly decreased in those cell lines co-cultured with cirrhotic splenocytes treated by celecoxib, p < 0.05. CONCLUSION: Splenomegaly contributed to the development of liver cirrhosis through enhancing oxidative stress in liver. Celecoxib could effectively ameliorate liver cirrhosis via reducing inflammatory cytokines and immune cells derived from spleen and suppressing oxidative stress.
Asunto(s)
Celecoxib/farmacología , Cirrosis Hepática/tratamiento farmacológico , Animales , Apoptosis/efectos de los fármacos , Celecoxib/metabolismo , China , Inhibidores de la Ciclooxigenasa 2/farmacología , Modelos Animales de Enfermedad , Células Estrelladas Hepáticas/metabolismo , Hepatocitos/metabolismo , Inflamación/tratamiento farmacológico , Hígado/patología , Cirrosis Hepática/metabolismo , Cirrosis Hepática Experimental/metabolismo , Masculino , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos , Bazo/patología , Esplenomegalia/complicaciones , Esplenomegalia/fisiopatología , Tioacetamida/farmacologíaRESUMEN
A 5-year-old male child of consanguineous parentage, without any adverse perinatal history, presented with progressive cognitive regression predominantly in the language and attention domains, for 2 years. He had simultaneous pyramidal and extrapyramidal involvement, frequent generalised tonic-clonic seizures and recurrent respiratory tract infections. Examination was significant for vertical supranuclear gaze palsy, coarse facial features and splenomegaly. Given the clinical features, in the background of consanguinity and mother's history of spontaneous pregnancy losses, inborn errors of metabolism were suspected. Following relevant investigations including tailored genetic study, Niemann-Pick disease type C (NPC) was diagnosed. Interestingly, MRI brain showed bilateral T2/fluid-attenuated inversion recovery claustrum hyperintensities, which are more commonly associated with autoimmune encephalitis and febrile infection-related epilepsy syndrome and not reported previously in NPC. Additionally, language regression as a presenting manifestation in NPC as opposed to classical dysarthria makes this case truly unique.
Asunto(s)
Claustro/diagnóstico por imagen , Enfermedad de Niemann-Pick Tipo C/diagnóstico , Atención , Preescolar , Disfunción Cognitiva/fisiopatología , Consanguinidad , Distonía/fisiopatología , Electroencefalografía , Humanos , Lenguaje , Imagen por Resonancia Magnética , Masculino , Espasticidad Muscular/fisiopatología , Enfermedad de Niemann-Pick Tipo C/diagnóstico por imagen , Enfermedad de Niemann-Pick Tipo C/fisiopatología , Parálisis Seudobulbar/fisiopatología , Infecciones del Sistema Respiratorio/fisiopatología , Convulsiones/fisiopatología , Esplenomegalia/fisiopatologíaRESUMEN
In systemic mastocytosis (SM), the clinical features and survival vary greatly. Patient-related factors determining the outcome in SM are largely unknown. Methods: We examined the impact of sex on the clinical features, progression-free survival (PFS), and overall survival (OS) in 3403 patients with mastocytosis collected in the registry of the European Competence Network on Mastocytosis (ECNM). The impact of cytogenetic and molecular genetic aberrations on sex differences was analyzed in a subset of patients. Results: Of all patients enrolled, 55.3% were females. However, a male predominance was found in a subset of advanced SM (AdvSM) patients, namely SM with an associated hematologic neoplasm (SM-AHN, 70%; p < 0.001). Correspondingly, organomegaly (male: 23% vs. female: 13%, p = 0.007) was more, whereas skin involvement (male: 71% vs. female: 86%, p = 0.001) was less frequent in males. In all patients together, OS (p < 0.0001) was significantly inferior in males, and also within the WHO sub-categories indolent SM, aggressive SM (ASM) and SM-AHN. PFS was significantly (p = 0.0002) worse in males when all patients were grouped together; due to low numbers of events, this significance persisted only in the subcategory smoldering SM. Finally, prognostically relevant cytogenetic abnormalities (10% vs. 5%, p = 0.006) or molecular aberrations (SRSF2/ASXL1/RUNX1 profile; 63% vs. 40%, p = 0.003) were more frequently present in males. Conclusions: Male sex has a major impact on clinical features, disease progression, and survival in mastocytosis. Male patients have an inferior survival, which seems related to the fact that they more frequently develop a multi-mutated AdvSM associated with a high-risk molecular background.
Asunto(s)
Aberraciones Cromosómicas , Mastocitosis Sistémica/genética , Factores Sexuales , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Subunidad alfa 2 del Factor de Unión al Sitio Principal/genética , Femenino , Enfermedades Gastrointestinales/fisiopatología , Neoplasias Hematológicas/complicaciones , Hepatomegalia/fisiopatología , Humanos , Lactante , Recién Nacido , Leucemia de Mastocitos/fisiopatología , Leucemia Mieloide Aguda/complicaciones , Masculino , Mastocitosis Sistémica/complicaciones , Mastocitosis Sistémica/mortalidad , Mastocitosis Sistémica/fisiopatología , Persona de Mediana Edad , Síndromes Mielodisplásicos/complicaciones , Pronóstico , Supervivencia sin Progresión , Proteínas Proto-Oncogénicas c-kit/genética , Proteínas Represoras/genética , Factores de Empalme Serina-Arginina/genética , Enfermedades de la Piel/fisiopatología , Esplenomegalia/fisiopatología , Tasa de Supervivencia , Adulto JovenRESUMEN
Light exerts critical non-visual effects on a multitude of physiological processes and behaviors, including sleep-wake behavior and cognitive function. In this study, we investigated the effects of continued exposure to different colors of light on cognitive function after sepsis in old mice. We found that exposure to red light, but not green light, exaggerated learning impairments and anxiety-like behaviors after sepsis. Red light also induced remarkable splenomegaly and altered the diversity and composition of the fecal microbiota. Pseudo germ-free mice transplanted with fecal bacteria from septic mice exposed to red light developed the same behavioral defects and splenomegaly as their donors. Intriguingly, splenectomy and subdiaphragmatic vagotomy reversed the learning impairments and anxiety-like behaviors resulting from red light exposure after sepsis. After subdiaphragmatic vagotomy, no differences in behavior or spleen size were observed among pseudo germ-free mice transplanted with fecal bacteria from septic mice exposed to different colors of light. Our results suggested that red light exposure after sepsis in old mice causes gut microbiota dysfunction, thus stimulating signaling through the subdiaphragmatic vagus nerve that induces splenomegaly and aggravates learning impairments and anxiety-like behaviors.
Asunto(s)
Ansiedad/etiología , Conducta Animal , Discapacidades para el Aprendizaje/etiología , Luz , Aprendizaje por Laberinto , Sepsis/complicaciones , Factores de Edad , Animales , Ansiedad/microbiología , Ansiedad/fisiopatología , Ansiedad/psicología , Modelos Animales de Enfermedad , Disbiosis , Heces/microbiología , Microbioma Gastrointestinal , Intestinos/microbiología , Discapacidades para el Aprendizaje/microbiología , Discapacidades para el Aprendizaje/fisiopatología , Discapacidades para el Aprendizaje/psicología , Masculino , Ratones Endogámicos C57BL , Prueba de Campo Abierto , Sepsis/microbiología , Sepsis/fisiopatología , Esplenomegalia/etiología , Esplenomegalia/fisiopatología , Nervio Vago/fisiopatologíaRESUMEN
OBJECTIVE: To develop a composite disease activity score for systemic JIA (sJIA) and to provide preliminary evidence of its validity. METHODS: The systemic Juvenile Arthritis Disease Activity Score (sJADAS) was constructed by adding to the four items of the original JADAS a fifth item that aimed to quantify the activity of systemic features. Validation analyses were conducted on patients with definite or probable/possible sJIA enrolled at first visit or at the time of a flare, who had active systemic manifestations, which should include fever. Patients were reassessed 2 weeks to 3 months after baseline. Three versions were examined, including ESR, CRP or no acute-phase reactant. RESULTS: A total of 163 patients were included at 30 centres in 10 countries. The sJADAS was found to be feasible and to possess face and content validity, good construct validity, satisfactory internal consistency (Cronbach's alpha 0.64-0.65), fair ability to discriminate between patients with different disease activity states and between those whose parents were satisfied or not satisfied with illness outcome (P < 0.0001 for both), and strong responsiveness to change over time (standardized response mean 2.04-2.58). Overall, these properties were found to be better than those of the original JADAS and of DAS for RA and of Puchot score for adult-onset Still's disease. CONCLUSION: The sJADAS showed good measurement properties and is therefore a valid instrument for the assessment of disease activity in children with sJIA. The performance of the new tool should be further examined in other patient cohorts that are evaluated prospectively.
Asunto(s)
Artralgia/fisiopatología , Artritis Juvenil/sangre , Artritis Juvenil/fisiopatología , Calidad de Vida , Anemia/sangre , Niño , Preescolar , Exantema/fisiopatología , Femenino , Fiebre/fisiopatología , Hepatomegalia/fisiopatología , Humanos , Hiperferritinemia/sangre , Linfadenopatía/fisiopatología , Masculino , Dimensión del Dolor , Rango del Movimiento Articular , Reproducibilidad de los Resultados , Serositis/fisiopatología , Índice de Severidad de la Enfermedad , Esplenomegalia/fisiopatología , Trombocitosis/sangreRESUMEN
BACKGROUND: There is a high prevalence of rare genetic disorders in the Middle East, and their study provides unique clinical and genetic insights. Autosomal recessive polycystic kidney disease (ARPKD) is one of the leading causes of kidney and liver-associated morbidity and mortality in Oman. We describe the clinical and genetic profile of cohort of ARPKD patients. METHODS: We studied patients with a clinical diagnosis of ARPKD (n = 40) and their relatives (parents (n = 24) and unaffected siblings (n = 10)) from 32 apparently unrelated families, who were referred to the National Genetic Centre in Oman between January 2015 and December 2018. Genetic analysis of PKHD1 if not previously known was performed using targeted exon PCR of known disease alleles and Sanger sequencing. RESULTS: A clinical diagnosis of ARPKD was made prenatally in 8 patients, 21 were diagnosed during infancy (0-1 year), 9 during early childhood (2-8 years) and 2 at later ages (9-13 years). Clinical phenotypes included polycystic kidneys, hypertension, hepatic fibrosis and splenomegaly. Twenty-four patients had documented chronic kidney disease (median age 3 years). Twenty-four out of the 32 families had a family history suggesting an autosomal recessive pattern of inherited kidney disease, and there was known consanguinity in 21 families (66%). A molecular genetic diagnosis with biallelic PKHD1 mutations was known in 18 patients and newly identified in 20 other patients, totalling 38 patients from 30 different families. Two unrelated patients remained genetically unsolved. The different PKHD1 missense pathogenic variants were: c.107C > T, p.(Thr36Met); c.406A > G, p.(Thr136Ala); c.4870C > T, p.(Arg1624Trp) and c.9370C > T, p.(His3124Tyr) located in exons 3, 6, 32 and 58, respectively. The c.406A > G, p.(Thr136Ala) missense mutation was detected homozygously in one family and heterozygously with a c.107C > T, p.(Thr36Met) allele in 5 other families. Overall, the most commonly detected pathogenic allele was c.107C > T; (Thr36Met), which was seen in 24 families. CONCLUSIONS: Molecular genetic screening of PKHD1 in clinically suspected ARPKD cases produced a high diagnostic rate. The limited number of PKHD1 missense variants identified in ARPKD cases suggests these may be common founder alleles in the Omani population. Cost effective targeted PCR analysis of these specific alleles can be a useful diagnostic tool for future cases of suspected ARPKD in Oman.
Asunto(s)
Hipertensión/fisiopatología , Cirrosis Hepática/fisiopatología , Riñón Poliquístico Autosómico Recesivo/fisiopatología , Insuficiencia Renal Crónica/fisiopatología , Esplenomegalia/fisiopatología , Adolescente , Niño , Preescolar , Consanguinidad , Femenino , Humanos , Lactante , Muerte del Lactante , Recién Nacido , Fallo Renal Crónico/fisiopatología , Cirrosis Hepática/congénito , Pulmón/anomalías , Masculino , Mutación Missense , Omán , Muerte Perinatal , Riñón Poliquístico Autosómico Recesivo/genética , Receptores de Superficie Celular/genéticaRESUMEN
BACKGROUND: Systemic juvenile idiopathic arthritis (sJIA) has many clinical features overlapping with familial Mediterranean fever (FMF), which is caused by mutations in MEFV gene. And FMF patients were easily misdiagnosed as sJIA in China. So we speculate that MEFV is critical genetic background for sJIA and influences patients' severity. In this study, we aim to figure out whether MEFV mutations are risk factor for the occurrence of sJIA and to study the association of MEFV mutations with disease severity of sJIA patients. METHODS: The present study includes 57 sJIA children and 2573 healthy controls. Odd ratio with 95% confidence interval based on allelic frequency of MEFV mutations or variants was used to evaluate their contribution to sJIA susceptibility. Meta-analysis was then performed to reach comprehensive conclusion. All included sJIA patients were grouped by presence and number of MEFV mutations. Clinical data and indicators of disease severity were compared among different groups. Multiple linear regression method was used to find out whether the number of MEFV variants is associated with the severity of sJIA. Kaplan-Meier curves and log rank test were used to estimate the probability of the first relapse. RESULTS: The MEFV mutations of our subjects predominantly existed in exons 2 and 3. No significant difference was found in allelic frequency between sJIA children and healthy controls. Meta-analysis demonstrated that p.M694V/I was a risk factor for sJIA (pooled OR: 7.13, 95% CI: 3.01-16.89). The relative period of activity was significantly lower in the one mutation group than those with more than one mutation (p = 0.0194). However, no relevance was found in multiple linear regression models. CONCLUSIONS: The mutation p.M694V/I in MEFV might be a risk factor for sJIA. SJIA patients carrying more than one heterozygous mutation in MEFV tend to be more severe than those containing only one, but studies in other cohort of patients need to be performed to validate it.
Asunto(s)
Artritis Juvenil/genética , Pirina/genética , Artritis Juvenil/fisiopatología , Estudios de Casos y Controles , Niño , Preescolar , Exantema/fisiopatología , Exones/genética , Femenino , Fiebre/fisiopatología , Predisposición Genética a la Enfermedad , Hepatomegalia/fisiopatología , Humanos , Lactante , Estimación de Kaplan-Meier , Modelos Lineales , Síndrome de Activación Macrofágica/fisiopatología , Masculino , Mutación , Oportunidad Relativa , Recurrencia , Serositis/fisiopatología , Esplenomegalia/fisiopatologíaRESUMEN
Felty's syndrome (FS) is a deforming disease, characterized by the triad of rheumatoid arthritis (RA), neutropenia, and splenomegaly. Currently, FS patients are treated mainly with immunosuppressants, such as methotrexate and glucocorticoids, which however are not suitable to some patients and may cause severe side effects. Here we report a clinical FS case that was treated with Tocilizumab (TCZ) successfully. The patient had symmetrical swelling and pain of multiple joints, deformity of elbow joints with obvious morning stiffness. Joint color Doppler ultrasound showed synovial hyperplasia and bone erosion of wrist and proximal interphalangeal joints and CT scan suggested splenomegaly. Further examination showed neutropenia and anemia, a high titer of anti-cyclic citrullinated peptide antibody, rheumatoid factor and anti-nuclear antibodies, positive p-ANCA, and elevated IgA and IgG. After treating with TCZ, the patient has been relieved of clinical symptoms. His spleen has recovered to normal size. The absolute neutrophil count (ANC) tended to be stable, and joint erosion did not deteriorate. We have reviewed the literatures on FS treatment with biological agents and found only a few reports using TNF-α antagonist and rituximab treating FS, but none with TCZ. So, it is the first time to report a successful FS case treated with TCZ. This case suggests that the TCZ may be a new choice for FS treatment, under the condition of closely monitoring the ANC.
Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Antirreumáticos/uso terapéutico , Síndrome de Felty/tratamiento farmacológico , Anciano , Anticuerpos Antiproteína Citrulinada/inmunología , Anticuerpos Anticitoplasma de Neutrófilos/inmunología , Anticuerpos Antinucleares/inmunología , Axila , Síndrome de Felty/inmunología , Síndrome de Felty/fisiopatología , Humanos , Leflunamida/uso terapéutico , Linfadenopatía/fisiopatología , Masculino , Metotrexato/uso terapéutico , Inducción de Remisión , Factor Reumatoide/inmunología , Esplenomegalia/diagnóstico por imagen , Esplenomegalia/fisiopatología , Resultado del TratamientoRESUMEN
Hb Dompierre [ß29(B11)GlyâArg, HBB: c.88G>C] is a rare ß-globin gene variant that was previously described in the heterozygous state in a 24-year-old female patient. It is defined in the HbVar database as being clinically and biologically asymptomatic. A few years after the first description, we had an opportunity of reassessing the index case because she presented with splenomegaly and clinical and biological manifestations of hemolysis. After ruling out the most common causes of hemolysis, further analyses on the variant hemoglobin (Hb) using brilliant cresyl blue staining, indicated that it showed mild instability, which may explain the clinical and biological manifestations. A structural bioinformatic analysis on the Hb variant suggested that the amino acid replacement may be deleterious to the integrity of the Hb. This report confirms the importance of completely characterizing all new Hb variants in order to guide the patients' clinical management and follow-up, as well as to provide the probands and their family members with appropriate genetic counseling.
Asunto(s)
Dolor Abdominal/genética , Hemoglobinopatías/genética , Hemoglobinas Anormales/genética , Mutación Missense , Esplenomegalia/genética , Globinas beta/genética , Dolor Abdominal/sangre , Dolor Abdominal/diagnóstico , Dolor Abdominal/fisiopatología , Adulto , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Femenino , Asesoramiento Genético , Hemoglobinopatías/sangre , Hemoglobinopatías/diagnóstico , Hemoglobinopatías/fisiopatología , Hemoglobinas Anormales/metabolismo , Hemólisis , Humanos , Modelos Moleculares , Fenotipo , Estabilidad Proteica , Esplenomegalia/sangre , Esplenomegalia/diagnóstico , Esplenomegalia/fisiopatología , Globinas beta/metabolismoRESUMEN
Glycogen storage diseases (GSDs) result from the deficiency of enzymes involved in glycogen synthesis and breakdown into glucose. Mutations in the gene PHKA2 encoding phosphorylase kinase regulatory subunit alpha 2 have been linked to GSD type IXa. We describe a family with two adult brothers with neonatal hepatosplenomegaly and later onset of hearing loss, cognitive impairment, and cerebellar involvement. Whole-exome sequencing was performed on both subjects and revealed a shared hemizygous missense variant (c.A1561G; p.T521A) in exon 15 of PHKA2. The phenotype broadens the clinical and magnetic resonance imaging spectrum of GSD type IXa to include later onset neurological manifestations.
Asunto(s)
Ataxia Cerebelosa/fisiopatología , Disfunción Cognitiva/fisiopatología , Epilepsia/fisiopatología , Enfermedades Genéticas Ligadas al Cromosoma X/fisiopatología , Enfermedad del Almacenamiento de Glucógeno/fisiopatología , Pérdida Auditiva Sensorineural/fisiopatología , Enfermedades del Sistema Nervioso Periférico/fisiopatología , Fosforilasa Quinasa/genética , Adulto , Encéfalo/diagnóstico por imagen , Incontinencia Fecal/fisiopatología , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Enfermedad del Almacenamiento de Glucógeno/genética , Hepatomegalia/fisiopatología , Humanos , Imagen por Resonancia Magnética , Masculino , Mutación Missense , Linaje , Fenotipo , Hermanos , Esplenomegalia/fisiopatología , Secuenciación del ExomaRESUMEN
Idiopathic portal hypertension (IPH) and extrahepatic portal venous obstruction (EHPVO) are prototype noncirrhotic causes of portal hypertension (PHT), characterized by normal hepatic venous pressure gradient, variceal bleeds, and moderate to massive splenomegaly with preserved liver synthetic functions. Infections, toxins, and immunologic, prothrombotic and genetic disorders are possible causes in IPH, whereas prothrombotic and local factors around the portal vein lead to EHPVO. Growth failure, portal biliopathy, and minimal hepatic encephalopathy are long-term concerns in EHPVO. Surgical shunts and transjugular intrahepatic portosystemic shunt resolve the complications secondary to PHT. Meso-Rex shunt is now the standard-of-care surgery in children with EHPVO.
Asunto(s)
Hipertensión Portal/fisiopatología , Cirrosis Hepática/fisiopatología , Pancitopenia/fisiopatología , Vena Porta , Esplenomegalia/fisiopatología , Trombosis de la Vena/fisiopatología , Animales , Enfermedades de las Vías Biliares/etiología , Enfermedades de las Vías Biliares/terapia , Manejo de la Enfermedad , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Várices Esofágicas y Gástricas , Hemorragia Gastrointestinal/etiología , Hemorragia Gastrointestinal/prevención & control , Hemorragia Gastrointestinal/terapia , Trastornos del Crecimiento/etiología , Encefalopatía Hepática/etiología , Encefalopatía Hepática/terapia , Humanos , Hipertensión Portal/complicaciones , Hipertensión Portal/diagnóstico , Hipertensión Portal/etiología , Hipertensión Portal/metabolismo , Hipertensión Portal/terapia , Cirrosis Hepática/complicaciones , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/metabolismo , Trasplante de Hígado , Metabolómica , Pancitopenia/complicaciones , Pancitopenia/diagnóstico , Pancitopenia/metabolismo , Derivación Portosistémica Quirúrgica , Derivación Portosistémica Intrahepática Transyugular , Calidad de Vida , Esplenomegalia/complicaciones , Esplenomegalia/diagnóstico , Esplenomegalia/metabolismo , Transcriptoma , Trombosis de la Vena/complicaciones , Trombosis de la Vena/diagnóstico , Trombosis de la Vena/metabolismo , Hipertensión Portal Idiopática no CirróticaRESUMEN
INTRODUCTION AND OBJECTIVES: Niemann-Pick disease type A (NPD-A) and B (NPD-B) are lysosomal storage diseases with a birth prevalence of 0.4-0.6/100,000. They are caused by a deficiency in acid sphingomyelinase, an enzyme encoded by SMPD1. We analyzed the phenotype and genotype of four unrelated Mexican patients, one with NPD-A and three with NPD-B. PATIENTS AND METHODS: Four female patients between 1 and 7 years of age were diagnosed with NPD-A or NPD-B by hepatosplenomegaly, among other clinical characteristics, and by determining the level of acid sphingomyelinase enzymatic activity and sequencing of the SMPD1 gene. Additionally, a 775bp amplicon of SMPD1 (from 11:6393835_6394609, including exons 5 and 6) was analyzed by capillary sequencing in a control group of 50 unrelated healthy Mexican Mestizos. RESULTS: An infrequent variant (c.1343A>G p.Tyr448Cys) was observed in two patients. One is the first NPD-A homozygous patient reported with this variant and the other a compound heterozygous NPD-B patient with the c.1829_1831delGCC p.Arg610del variant. Another compound heterozygous patient had the c.1547A>G p.His516Arg variant (not previously described in affected individuals) along with the c.1805G>A p.Arg602His variant. A new c.1263+8C>T pathogenic variant was encountered in a homozygous state in a NPD-B patient. Among the healthy control individuals there was a heterozygous carrier for the c.1550A>T (rs142787001) pathogenic variant, but none with the known pathogenic variants in the 11:6393835_6394609 region of SMPD1. CONCLUSIONS: The present study provides further NPD-A or B phenotype-genotype correlations. We detected a heterozygous carrier with a pathogenic variant in 1/50 healthy Mexican mestizos.
Asunto(s)
Enfermedad de Niemann-Pick Tipo A/genética , Enfermedad de Niemann-Pick Tipo B/genética , Esfingomielina Fosfodiesterasa/genética , Adolescente , Adulto , Niño , Preescolar , Epistaxis/fisiopatología , Femenino , Tamización de Portadores Genéticos , Genotipo , Trastornos del Crecimiento/fisiopatología , Voluntarios Sanos , Hepatomegalia/fisiopatología , Heterocigoto , Humanos , Lactante , Hígado/patología , Hígado/ultraestructura , México , Enfermedad de Niemann-Pick Tipo A/metabolismo , Enfermedad de Niemann-Pick Tipo A/patología , Enfermedad de Niemann-Pick Tipo A/fisiopatología , Enfermedad de Niemann-Pick Tipo B/metabolismo , Enfermedad de Niemann-Pick Tipo B/patología , Enfermedad de Niemann-Pick Tipo B/fisiopatología , Fenotipo , Esfingomielina Fosfodiesterasa/metabolismo , Esplenomegalia/fisiopatología , Adulto JovenRESUMEN
BACKGROUND AND AIM: Idiopathic portal hypertension (IPH) refers to a relatively rare condition characterized by intrahepatic portal hypertension in the absence of underlying disease such as liver cirrhosis. METHODS: We retrospectively reviewed 338 patients with IPH that were diagnosed at the pathological consultation center of our hospital. RESULTS: The ratio of male to female patients was 1:1. Mean age at onset was 35.1 ± 16.5 years; male patients on average were 12 years younger than female patients at onset. The median duration from onset to IPH diagnosis was 12 months. In 50 patients, medication use may have been an etiological factor. The most common clinical manifestations were splenomegaly (91.3%) and hypersplenism (68.9%); 57.0% patients presented varicosis, while 25.1% patients had a history of variceal bleeding. Nodular regenerative hyperplasia was found in 22.2% liver biopsies. Among patients for whom laboratory data were available, 65.0%, 50.3%, and 71.4% patients presented leukopenia, anemia, and thrombocytopenia due to hypersplenism. Liver function was mostly in the compensated stage. Female patients showed worse leukopenia and anemia, while male patients were more likely to have abnormal serum transaminase and bilirubin levels. Sixty-seven patients received surgical or interventional treatment. CONCLUSIONS: High-quality liver biopsy, detailed clinical information, and expert pathologist are necessary for diagnosis of IPH. IPH can occur concurrently with other liver disease such as hepatitis and drug-induced liver injury. Medication appears to be an important etiological factor for IPH in China. Management approach was largely focused on treatment of portal hypertension and its complications.
Asunto(s)
Hipertensión Portal/patología , Cirrosis Hepática/patología , Hígado/patología , Pancitopenia/patología , Esplenomegalia/patología , Adolescente , Adulto , Biopsia , China/epidemiología , Femenino , Humanos , Hipertensión Portal/epidemiología , Hipertensión Portal/fisiopatología , Hipertensión Portal/terapia , Cirrosis Hepática/epidemiología , Cirrosis Hepática/fisiopatología , Cirrosis Hepática/terapia , Pruebas de Función Hepática , Masculino , Persona de Mediana Edad , Pancitopenia/epidemiología , Pancitopenia/fisiopatología , Pancitopenia/terapia , Presión Portal , Valor Predictivo de las Pruebas , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Esplenomegalia/epidemiología , Esplenomegalia/fisiopatología , Esplenomegalia/terapia , Adulto Joven , Hipertensión Portal Idiopática no CirróticaRESUMEN
OBJECTIVES: One of the striking features of splenic imaging is variable heterogeneous gyriform arterial enhancement on dynamic computed tomography (CT). We speculated that these patterns of arterial enhancement may reflect changes in splenic micro-circulation related to changes in portal venous pressure. PATIENTS AND METHODS: To test this hypothesis, we evaluated arterial phase CT scans performed before and after liver transplantation (n=91), as this is the most effective way of alleviating portal hypertension. We developed novel grading systems to assess heterogeneity. Two control groups were used: patients with cirrhosis undergoing transarterial chemoembolization (TACE) (n=28) and patients with cirrhosis on the liver transplant waiting list who had repeated CT scans (n=28). RESULTS: Splenic arterial heterogeneity increased in 55% of transplant patients compared with 14% in the TACE patients and 4% in the waiting list patients (P<0.0001). Mean Hounsfield units in areas of splenic enhancement were 71.7±2 before transplant and 90.1±2.5 after transplant (P<0.01). In contrast, there were no significant changes following TACE (86.3±4.2 vs. 83.5±4.5; P=NS) or in waiting list patients (80.9±4.6 vs. 73.8±3.7; P=NS). CONCLUSION: We have shown the heterogeneous gyriform enhancement patterns significantly increase following liver transplantation but not after TACE or in waiting list patients. We suggest that these changes are due to the reduction in portal venous pressure and likely reflect changes in splenic micro-circulation. These changes may be important in the pathophysiology of hypersplenism.
Asunto(s)
Carcinoma Hepatocelular/diagnóstico por imagen , Angiografía por Tomografía Computarizada , Hipertensión Portal/diagnóstico por imagen , Cirrosis Hepática/diagnóstico por imagen , Neoplasias Hepáticas/diagnóstico por imagen , Presión Portal , Arteria Esplénica/diagnóstico por imagen , Esplenomegalia/diagnóstico por imagen , Anciano , Carcinoma Hepatocelular/etiología , Carcinoma Hepatocelular/fisiopatología , Carcinoma Hepatocelular/terapia , Estudios de Casos y Controles , Quimioembolización Terapéutica , Femenino , Humanos , Hipertensión Portal/etiología , Hipertensión Portal/fisiopatología , Hipertensión Portal/terapia , Cirrosis Hepática/complicaciones , Cirrosis Hepática/fisiopatología , Cirrosis Hepática/terapia , Neoplasias Hepáticas/etiología , Neoplasias Hepáticas/fisiopatología , Neoplasias Hepáticas/terapia , Trasplante de Hígado , Masculino , Microcirculación , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Circulación Esplácnica , Arteria Esplénica/fisiopatología , Esplenomegalia/etiología , Esplenomegalia/fisiopatología , Resultado del Tratamiento , Listas de EsperaRESUMEN
Myelofibrosis (MF) is a clinical manifestation of chronic BCR-ABL1-negative chronic myeloproliferative neoplasms. Splenomegaly is one of the major clinical manifestations of MF and is directly linked to splenic extramedullary hematopoiesis (EMH). EMH is associated with abnormal trafficking patterns of clonal hematopoietic cells due to the dysregulated bone marrow (BM) microenvironment leading to progressive splenomegaly. Several recent data have emphasized the role of several cytokines for splenic EMH. Alteration of CXCL12/CXCR4 pathway could also lead to splenic EMH by migrated clonal hematopoietic cells from BM to the spleen. Moreover, low Gata1 expression was found to be significantly associated with the EMH. Several gene mutations were found to be associated with significant splenomegaly in MF. In recent data, JAK2V617F homozygous mutation was associated with a larger spleen size. In other data, CALR mutations in MF were signigicantly associated with longer larger splenomegaly-free survivals than others. In addition, MF patients with ≥1 mutations in AZXL1, EZH1 or IDH1/2 had significantly low spleen reduction response in ruxolitinib treatment. Developments of JAK inhibitors, such as ruxolitinib, pacritinib, momelotinib, and febratinib enabled the effective management in MF patients. Especially, significant spleen reduction responses of the drugs were demonstrated in several randomized clinical studies, although those could not eradicate allele burdens of MF.
Asunto(s)
Hematopoyesis Extramedular/fisiología , Quinasas Janus/genética , Mielofibrosis Primaria/genética , Mielofibrosis Primaria/patología , Esplenomegalia/genética , Médula Ósea/patología , Movimiento Celular , Quimiocina CXCL12/metabolismo , Hematopoyesis Extramedular/efectos de los fármacos , Humanos , Inhibidores de las Cinasas Janus/farmacología , Inhibidores de las Cinasas Janus/uso terapéutico , Mutación , Mielofibrosis Primaria/tratamiento farmacológico , Mielofibrosis Primaria/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto , Receptores CXCR4/metabolismo , Bazo/patología , Esplenomegalia/tratamiento farmacológico , Esplenomegalia/fisiopatologíaRESUMEN
Primary graft failure can be a cause of early morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), as it leads to a high risk of severe infections and bleeding. Splenomegaly is associated with primary graft failure in patients of myelofibrosis, but the association between splenomegaly and outcomes after HSCT in patients with myeloid malignancies has not been previously evaluated. The aim of this study was to investigate the effect of spleen volume on engraftment kinetics in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We enrolled 85 patients. The median spleen volume was 146 cm3 (quartile 88-201 cm3). The adjusted hazard ratios for neutrophil and platelet engraftments were 0.17 (0.07-0.40, p < 0.001) and 0.19 (0.05-0.69, p = 0.011), respectively, for the high-risk group, at a cutoff splenic volume of 320 cm3. Overall survival at 3 years after HSCT was significantly poor in the high-risk group with an adjusted hazard ratio of 13.8 (2.61-72.4, p = 0.002). Enlarged spleen was associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic HSCT in patients of AML and MDS.
Asunto(s)
Plaquetas/inmunología , Rechazo de Injerto/prevención & control , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Leucemia Mieloide Aguda/terapia , Síndromes Mielodisplásicos/terapia , Neutrófilos/inmunología , Esplenomegalia/etiología , Recuento de Células Sanguíneas , Estudios de Cohortes , Femenino , Rechazo de Injerto/epidemiología , Rechazo de Injerto/inmunología , Rechazo de Injerto/fisiopatología , Humanos , Imagenología Tridimensional , Japón/epidemiología , Leucemia Mieloide Aguda/inmunología , Masculino , Síndromes Mielodisplásicos/inmunología , Recuento de Plaquetas , Estudios Retrospectivos , Riesgo , Índice de Severidad de la Enfermedad , Bazo/diagnóstico por imagen , Esplenomegalia/diagnóstico por imagen , Esplenomegalia/epidemiología , Esplenomegalia/fisiopatología , Análisis de Supervivencia , Tomografía Computarizada por Rayos X , Trasplante Homólogo/efectos adversosRESUMEN
BACKGROUND: Idiopathic portal hypertension (IPH) and extrahepatic portal venous obstruction (EHPVO) are non-cirrhotic vascular causes of portal hypertension (PHT). Variceal bleed and splenomegaly are the commonest presentations. AIM: The present review is intended to provide the existing literature on etiopathogenesis, clinical profile, diagnosis, natural history and management of IPH and EHPVO. RESULTS: IPH and EHPVO are both characterized by normal hepatic venous pressure gradient, moderate to massive splenomegaly with preserved liver synthetic functions. While the level of block in IPH is presinusoidal, in EHPVO it is at prehepatic level. Infections, autoimmunity, drugs, immunodeficiency and prothrombotic states are possible etiological agents in IPH. Contrastingly in EHPVO, prothrombotic disorders and local factors around the portal vein are the incriminating factors. Diagnosis is often clinical, supported by simple radiological tools. Natural history is defined by episodes of variceal bleed and symptoms related to enlarged spleen. Growth failure, portal biliopathy and minimal hepatic encephalopathy are additional concerns in EHPVO. Long-term survival is reasonably good with endoscopic surveillance; however, parenchymal extinction leading to decompensation is seen in a minority of patients in both the disorders. Surgical shunts revert the complications secondary to PHT. Meso-Rex shunt has become the standard surgery in children with EHPVO. CONCLUSION: This review gives a detailed summary of these two vascular conditions of liver-IPH and EHPVO. Further research is needed to understand the pathogenesis and natural history of these disorders.